Literature DB >> 28039046

Bone Quality Assessment as Measured by Trabecular Bone Score in Patients With End-Stage Renal Disease on Dialysis.

Maria P Yavropoulou1, Vasilios Vaios2, Maria Pikilidou3, Ioannis Chryssogonidis4, Melina Sachinidou4, Symeon Tournis5, Konstantinos Makris5, Kalliopi Kotsa1, Michalis Daniilidis3, Afroditi Haritanti4, Vassilios Liakopoulos6.   

Abstract

Patients with end-stage renal disease (ESRD) on maintenance hemodialysis (HD) exhibit osteoporosis and increased fracture risk. Dual-energy X-ray absorptiometry scan measurements and calculation of fracture risk assessment toll score underestimate fracture risk in these patients and do not estimate bone quality. Trabecular bone score (TBS) has been recently proposed as an indirect measure of bone microarchitecture. In this study, we investigated alterations of bone quality in patients with ESRD on HD, using TBS. Fifty patients with ESRD on HD, with a mean age 62 years, and 52 healthy individuals matched for age, body mass index, and gender, were enrolled. All participants had a bone mineral density (BMD) measurement by dual-energy X-ray absorptiometry scan at the lumbar spine, femoral neck, total hip, and 1/3 radius. TBS was evaluated using TBS iNsight. Serum fetuin-A and plasma fibroblast growth factor-23 (FGF-23) (C-terminal) were also measured. Patients on dialysis had significantly lower BMD values at all skeletal sites measured. Plasma FGF-23 levels significantly increased and serum fetuin-Α significantly decreased in patients on dialysis compared with controls. TBS was significantly reduced in patients on dialysis compared with controls (1.11 ± 0.16 vs 1.30 ± 0.13, p < 0.001, respectively) independently of age; BMD; duration of dialysis; and serum levels of alkaline phosphatase, 25-OH-vitamin D, parathyroid hormone, fetuin-A, or plasma FGF-23. Patients on HD who were diagnosed with an osteoporotic vertebral fracture had numerically lower TBS values, albeit without reaching statistical significance, compared with patients on dialysis without a fracture (1.044 ± 0.151 vs 1.124 ± 0.173, respectively, p = 0.079). Bone microarchitecture, as assessed by TBS, is significantly altered in ESRD on patients on HD independently of BMD values and metabolic changes that reflect chronic kidney disease-mineral and bone disorder.
Copyright © 2016 International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone mineral density; chronic kidney disease; hemodialysis; osteoporosis; trabecular bone score

Mesh:

Substances:

Year:  2016        PMID: 28039046     DOI: 10.1016/j.jocd.2016.11.002

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.617


  13 in total

1.  Loss of bone mineral density and trabecular bone score in elderly hemodialysis patients: a 2-year follow-up, prospective, single-centre study.

Authors:  Ludmila Brunerová; Petr Kasalický; Jana Verešová; Renata Lažanská; Jana Potočková; Ivan Rychlík
Journal:  Int Urol Nephrol       Date:  2020-02-03       Impact factor: 2.370

2.  Predictors of bone fractures in a single-centre cohort of hemodialysis patients: a 2-year follow-up study.

Authors:  Ludmila Brunerová; Renata Lažanská; Petr Kasalický; Jana Verešová; Jana Potočková; Alena Fialová; Ivan Rychlík
Journal:  Int Urol Nephrol       Date:  2018-08-16       Impact factor: 2.370

3.  Fibroblast Growth Factor 23 and Klotho Are Associated With Trabecular Bone Score but Not Bone Mineral Density in the Early Stages of Chronic Kidney Disease: Results of the Cross-Sectional Study.

Authors:  Z Kužmová; M Kužma; A Gažová; M Kovářová; P Jackuliak; Z Killinger; J Kyselovič; J Payer
Journal:  Physiol Res       Date:  2021-11-30       Impact factor: 1.881

4.  The trabecular bone score is associated with bone mineral density, markers of bone turnover and prevalent fracture in patients with end stage kidney disease.

Authors:  J Aleksova; S Kurniawan; G J Elder
Journal:  Osteoporos Int       Date:  2018-03-19       Impact factor: 4.507

Review 5.  The Use of Imaging Techniques in Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD)-A Systematic Review.

Authors:  Ana Pimentel; Jordi Bover; Grahame Elder; Martine Cohen-Solal; Pablo Antonio Ureña-Torres
Journal:  Diagnostics (Basel)       Date:  2021-04-26

6.  Trabecular bone score may indicate chronic kidney disease-mineral and bone disorder (CKD-MBD) phenotypes in hemodialysis patients: a prospective observational study.

Authors:  Hyo Jin Yun; Soo Ryeong Ryoo; Jung-Eun Kim; Yong Jun Choi; Inwhee Park; Gyu-Tae Shin; Heungsoo Kim; Jong Cheol Jeong
Journal:  BMC Nephrol       Date:  2020-07-25       Impact factor: 2.388

Review 7.  Review on the Utility of Trabecular Bone Score, a Surrogate of Bone Micro-architecture, in the Chronic Kidney Disease Spectrum and in Kidney Transplant Recipients.

Authors:  Enisa Shevroja; Olivier Lamy; Didier Hans
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-24       Impact factor: 5.555

8.  Circulating microRNAs Related to Bone Metabolism in HIV-Associated Bone Loss.

Authors:  Maria P Yavropoulou; Artemis Kolynou; Polyzois Makras; Maria Pikilidou; Sideris Nanoudis; Lemonia Skoura; Olga Tsachouridou; Georgios Ntritsos; Alexandros Tzallas; Dimitrios G Tsalikakis; Olga Tsave; Simeon Metallidis; Dimitrios Chatzidimitriou
Journal:  Biomedicines       Date:  2021-04-20

9.  Expression of Circulating MicroRNAs Linked to Bone Metabolism in Chronic Kidney Disease-Mineral and Bone Disorder.

Authors:  Maria P Yavropoulou; Vasilios Vaios; Polyzois Makras; Panagiotis Georgianos; Anastasios Batas; Dimitrios Tsalikakis; Alexandros Tzallas; Georgios Ntritsos; Stefanos Roumeliotis; Theodoros Eleftheriadis; Vassilios Liakopoulos
Journal:  Biomedicines       Date:  2020-12-12

10.  Bone turnover correlates with bone quantity but not bone microarchitecture in chronic hemodialysis.

Authors:  Roxana Dusceac; Dan Alexandru Niculescu; Ramona Dobre; Madalina Cristina Sorohan; Andra Caragheorgheopol; Catalin Tacu; Cristiana David; Catalina Poiana
Journal:  J Bone Miner Metab       Date:  2020-03-06       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.